A fusion protein with improved thrombolytic effect and low bleeding risk

 

 Buy Article Permissions and Reprints

Summary

To resolve the therapeutic dilemma between efficacy of thrombolysis and bleeding risk associated with the use of a combination of thrombolytic and anticoagulant treatments, we created a fusion protein. Staphylokinase was fused to the N-terminus of hirudin using thrombin recognition sequence as linker peptide, resulting in a fusion protein STH.We hypothesised that STH would be cleaved by thrombin at the thrombus site, releasing staphylokinase and hirudin to perform bifunctionally, and attenuating bleeding risk. SDS-PAGE andWestern blot analyses indicated that the linker peptide could be specially recognised and cleaved by thrombin. Amidolytic and thromboelastogram assays showed that the N-terminus of hirudin in STH was blocked by staphylokinase and linker peptide, impeding hirudin’s anticoagulant activity. Once cleaved, STH displayed 35.7% of the anticoagulant activity of equimolar hirudin and exhibited anticoagulant effects in the fibrin clot lysis assay.Thrombin-binding and fibrin clot lysis assays showed that the C-terminus of hirudin retained its high affinity for thrombin. Moreover, STH showed improved thrombolytic effects and a lower bleeding risk in animals. Thus, STH may have the capacity to perform bifunctionally and release anticoagulant activity in a thrombus-targeted manner in vivo, which may reduce the bleeding risk that often accompanies high thrombolytic efficacy in the treatment of thromboembolic diseases.

^* These authors contributed equally to this work.

• References

• 1 Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-628.
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 The InTIME-IIinvestigators. Intravenous NPA for the treatment of infarcting myocardium early, InTIMEII, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-2013.
  CrossrefPubMedGoogle Scholar
• 3 Fitchett D. Tailored antithrombotic therapy for acute coronary syndromes. Expert Rev Cardiovasc Ther 2008; 06: 935-944.
  CrossrefPubMedGoogle Scholar
• 4 French JK, Edmond JJ, Gao W. et al. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. Am J Cardiovasc Drugs 2004; 04: 107-115.
  CrossrefPubMedGoogle Scholar
• 5 Eikelboom JW, Quinlan DJ, Mehta SR. et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction-a Metaanalysis of the randomized trials. Circulation 2005; 112: 3855-3867.
  CrossrefPubMedGoogle Scholar
• 6 Wong CK, White HD. Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine. Am J Cardiovasc Drugs 2007; 07: 249-257.
  CrossrefPubMedGoogle Scholar
• 7 Icke C, Schlott B, Ohlenschlager O. et al. Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations. Mol Pharmacol 2002; 62: 203-209.
  CrossrefPubMedGoogle Scholar
• 8 Lian Q, Szarka SJ, Ng KK. et al. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots. J Biol Chem 2003; 278: 26677-26686.
  CrossrefPubMedGoogle Scholar
• 9 Szemraj J, Walkowiak B, Kawecka I. et al. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant I. In vitro study. J Thromb Haemost 2005; 03: 2156-2165.
  CrossrefPubMedGoogle Scholar
• 10 Wirsching F, Luge C, Schwienhors A. Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen-activating potential. Mol Gen Metab 2002; 75: 250-259.
  CrossrefPubMedGoogle Scholar
• 11 Sau-Ching W, Francis J, Sui-Lam W. A fast-acting,modular-structured staphylokinase fusion with Kringle 1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy. J Bio Chem 2003; 278: 18199-18205.
  CrossrefPubMedGoogle Scholar
• 12 Szemraj J, Stankiewicz A, Rozmyslowicz-Szerminska W. et al. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant An in-vivo study. Thromb Haemost 2007; 97: 1037-1045.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Shi BX, Yu AP, Liu YY. et al. Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk. J Thromb Thrombolysis 2007; 24: 283-292.
  CrossrefPubMedGoogle Scholar
• 14 Yu AP, Zhang CL, Dong CN. et al. Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release of anticoagulant activity. Chin J Biotech 2008; 24: 1955-1961.
  PubMedGoogle Scholar
• 15 Zhang CL, Yu AP, Yuan B. et al. Construction and functional evaluation of hirudin derivatives with low bleeding risk. Thromb Haemost 2008; 99: 324-330.
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Sheffield WP, Eltringham-Smith LJ, Gatalance S. et al. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo. Thromb Haemost 2009; 101: 867-877.
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 2007; 116: 305-315.
  CrossrefPubMedGoogle Scholar
• 18 Elg M, Borjesson I, Carlsson S. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat. Biopharm Drug Dispos 2003; 24: 251-257.
  CrossrefPubMedGoogle Scholar
• 19 Monreal M, Silveira P, Monreal L. et al. Comparative study on the antithrombotic efficacy of four low-molecular-weight heparins in three different models of experimental venous thrombosis. Haemostasis 1991; 21: 91-97.
  PubMedGoogle Scholar
• 20 Wallace A, Dennis S, Hofsteenge J. et al. Contribution of the N-terminal region of hirudin to its interaction with thrombin. Biochemistry 1989; 28: 10079-10084.
  CrossrefPubMedGoogle Scholar
• 21 Fortkamp E, Rieger M, Heisterberg-Moutses G. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 05: 511-517.
  CrossrefPubMedGoogle Scholar